- Home
- CRVO vs ALLK Comparison
CRVO vs ALLK Comparison
Compare CRVO & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- ALLK
- Stock Information
- Founded
- CRVO 2001
- ALLK 2012
- Country
- CRVO United States
- ALLK United States
- Employees
- CRVO N/A
- ALLK N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- ALLK Health Care
- Exchange
- CRVO Nasdaq
- ALLK Nasdaq
- Market Cap
- CRVO 98.3M
- ALLK 101.0M
- IPO Year
- CRVO N/A
- ALLK 2018
- Fundamental
- Price
- CRVO $1.95
- ALLK $1.12
- Analyst Decision
- CRVO Buy
- ALLK Hold
- Analyst Count
- CRVO 8
- ALLK 5
- Target Price
- CRVO $38.75
- ALLK $1.67
- AVG Volume (30 Days)
- CRVO 922.0K
- ALLK 306.2K
- Earning Date
- CRVO 11-12-2024
- ALLK 11-06-2024
- Dividend Yield
- CRVO N/A
- ALLK N/A
- EPS Growth
- CRVO N/A
- ALLK N/A
- EPS
- CRVO N/A
- ALLK N/A
- Revenue
- CRVO $10,066,550.00
- ALLK N/A
- Revenue This Year
- CRVO $34.17
- ALLK N/A
- Revenue Next Year
- CRVO N/A
- ALLK N/A
- P/E Ratio
- CRVO N/A
- ALLK N/A
- Revenue Growth
- CRVO 116.29
- ALLK N/A
- 52 Week Low
- CRVO $1.80
- ALLK $0.54
- 52 Week High
- CRVO $26.38
- ALLK $3.36
- Technical
- Relative Strength Index (RSI)
- CRVO 24.32
- ALLK 52.99
- Support Level
- CRVO $1.80
- ALLK $1.00
- Resistance Level
- CRVO $2.10
- ALLK $1.11
- Average True Range (ATR)
- CRVO 1.45
- ALLK 0.08
- MACD
- CRVO -0.64
- ALLK 0.00
- Stochastic Oscillator
- CRVO 0.95
- ALLK 47.73
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.